Member companies of the UK BioIndustry Association say they want the new Innovative Licensing and Access Pathway (ILAP) to remain open for products in both early and late-stage development, and that “partnership and engagement” among all the stakeholders involved are vital if the new pathway is to be successful.
Industry feedback on the ILAP, which was introduced by the regulator, the MHRA, in January this year, was shared at...








